Karl Donn

Karl Donn is currently Vice President, Respiratory R&D. He led the drug discovery program that resulted in the selection of P-1037 as a potent and durable epithelial sodium channel blocker for inhaled delivery to patients with cystic fibrosis, COPD and other respiratory diseases. He continues to lead the development of P-1037 through clinical trials. He also leads tPAD clinical development and led a variety of discovery and early development programs at Parion. Karl has over 30 years of drug development experience in both small and large pharmaceutical companies. Prior to joining Parion, he was the VP, of Global Project & Portfolio Management at GlaxoSmithKline where he developed and implemented an industry-leading R&D-wide project management organization that spanned all therapeutic areas at all R&D centers. He led several project teams, including Cialis, Zomig and Avodart®. Prior to his project leadership roles, Karl created and led the Clinical Pharmacokinetics / Pharmacodynamics department and provided PK/PD expertise to several projects including Zantac, Ceftin, Imitrex, Ultiva, Epivir, Wellbutrin, and Cerebyx. Karl earned a BS in Pharmacy from SUNY at Buffalo and an MS and Ph.D. from UNC-Chapel Hill School of Pharmacy. He completed a residency in clinical pharmacy at Moses Cone Hospital and a Fellowship in Clinical Drug Research at Burroughs Wellcome Company. He serves on the National Industry Advisory Council for the State University of New York at Buffalo and was recognized by UNC-Chapel Hill School of Pharmacy with their distinguished alumnus award.